Addressing a Global Need with RNA Vaccines and Immunotherapies

Chris Pirie, co-founder and chief operating officer of HDT Bio, discusses the problem antibiotic resistance in developing nations, its platform technology for producing safe and stable RNA vaccines, and the potential to use the same platform to produce immunotherapies for cancer.